Tourmaline Bio Q3 EPS Forecast Increased by Lifesci Capital

Key Points

• Lifesci Capital has raised its Q3 2025 earnings per share estimate for Tourmaline Bio from ($0.98) to ($0.91), indicating an improved outlook for the company.
• Tourmaline Bio's stock is currently rated as a "Buy" by seven analysts, with target prices ranging from $50.00 to $70.00.
• The company reported a Q2 earnings result of ($0.90) per share, which was better than the consensus estimate of ($0.94).

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Lifesci Capital upped their Q3 2025 earnings per share (EPS) estimates for Tourmaline Bio in a research report issued on Wednesday, August 13th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($0.91) for the quarter, up from their prior estimate of ($0.98). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Lifesci Capital also issued estimates for Tourmaline Bio's Q4 2025 earnings at ($0.95) EPS and FY2025 earnings at ($3.68) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.04.

Other equities analysts have also issued research reports about the company. Chardan Capital reiterated a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Thursday, August 14th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Tourmaline Bio in a report on Thursday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $50.14.

Tourmaline Bio Stock Performance

Shares of NASDAQ TRML traded up $0.2240 during trading hours on Monday, reaching $22.6840. 37,981 shares of the stock were exchanged, compared to its average volume of 287,237. The firm has a market capitalization of $582.64 million, a price-to-earnings ratio of -6.60 and a beta of 2.04. Tourmaline Bio has a 52 week low of $11.56 and a 52 week high of $29.79. The stock's fifty day simple moving average is $19.25 and its 200 day simple moving average is $16.69.

Hedge Funds Weigh In On Tourmaline Bio

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its stake in shares of Tourmaline Bio by 34.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company's stock valued at $34,000 after purchasing an additional 535 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Tourmaline Bio by 35.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company's stock valued at $51,000 after acquiring an additional 846 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Tourmaline Bio by 10.8% during the 4th quarter. Invesco Ltd. now owns 12,155 shares of the company's stock valued at $247,000 after acquiring an additional 1,181 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Tourmaline Bio by 297.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after acquiring an additional 1,232 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Tourmaline Bio by 3.9% during the 1st quarter. SG Americas Securities LLC now owns 36,180 shares of the company's stock valued at $550,000 after acquiring an additional 1,368 shares in the last quarter. Institutional investors own 91.89% of the company's stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.